Regulatory Guidance Monthly Review - April 2020

April 2020 


Blog Image-Regulatory Guidanc eMonthly Review_2020-1

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided for both COVID-19 related and non-COVID-19 related programs in April 2020.

 

Blog Image-Regulatory Guidanc eMonthly_FDAupdates-1

 

Finalized Draft Guidance Documents:

 

Exemption and Exclusion from Certain Requirements of the Drug Supply Chain Security Act During the COVID-19 Public Health Emergency Guidance for Industry (Published 30Apr2020)

Download Guidance

 

Temporary Policy on Repackaging or Combining Propofol Drug Products During the COVID-19 Public Health Emergency Guidance for Industry (Published 24Apr2020)

Download Guidance

 

Nonbinding Feedback After Certain FDA Inspections of Device Establishments Guidance for Industry and Food and Drug Administration Staff (Published 22Apr2020)

Download Guidance

 

Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency Guidance for Industry (Published 20Apr2020)

Download Guidance

 

Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Outsourcing Facilities During the COVID-19 Public Health Emergency Guidance for Industry (Published 16Apr2020)

Download Guidance

 

Product-Specific Guidances; Guidance for Industry; Availability (Published 14Apr2020)

View Federal Register

 

Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products Guidance for Industry (Published 13Apr2020)

Download Guidance

 

Temporary Policy Regarding NonStandard PPE Practices for Sterile Compounding by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency Guidance for Industry (Published 10Apr2020)

Download Guidance

 

Policy for the Temporary Use of Portable Cryogenic Containers Not in Compliance With 21 CFR 211.94(e)(1) For Oxygen and Nitrogen During the COVID-19 Public Health Emergency Guidance for Industry (Published 09Apr2020)

Download Guidance

 

Investigational COVID-19 Convalescent Plasma Guidance for Industry (Published 08Apr2020)

Download Guidance

 

Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act Guidance for Industry (Published 03Apr2020)

Download Guidance

 

Alternative Procedures for Blood and Blood Components During the COVID-19 Public Health Emergency Guidance for Industry (Published 02Apr2020)

Download Guidance

 

Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components Guidance for Industry (Published 02Apr2020)

Download Guidance

 

Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry (Published 02Apr2020)

Download Guidance

 

Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria Guidance for Industry (Published 02Apr2020)

Download Guidance

 


New Draft Guidance Documents:

 

Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA or ANDA: Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE (Published 21Apr2020)

Download DRAFT Guidance

 


 

Blog Image-Regulatory Guidanc eMonthly_Regulatory Agencies in the News

 

FDA lifts drug supply chain security requirements for COVID-19 products (Published 30Apr2020)

View RAPS Article

COVID-19 vaccine tracker (Published 30Apr2020)

View Tracker on RAPS.org

 

EMA explains new pharmacovigilance inspection follow-up procedures (Published 30Apr2020)

View RAPS Article

 

EU Regulatory Roundup: Denmark permits remote SDV during COVID-19 pandemic (Published 30Apr2020)

View RAPS Article

 

CMDh explains impact of COVID-19 on mutual recognition, decentralised procedures (Published 29Apr2020)

View RAPS Article

 

FDA guides generic drugmakers on bioequivalence study disruptions amid COVID-19 (Published 29Apr2020)

View RAPS Article

 

FDA, EU authorities update guidance on clinical trials during COVID-19 (Published 28Apr2020)

View RAPS Article

 

ICMRA members pledge clinical, regulatory support for COVID-19 products (Published 28Apr2020)

View RAPS Article

 

Asia Regulatory Roundup: TGA begins virtual GMP inspections of domestic manufacturers (Published 28Apr2020)

View RAPS Article

 

FDA and China’s NMPA expedite COVID-19 emergency approvals (Published 28Apr2020)

View RAPS Article

 

Coronavirus (COVID-19) Update: FDA Reiterates Importance of Close Patient Supervision for ‘Off-Label’ Use of Antimalarial Drugs to Mitigate Known Risks, Including Heart Rhythm Problems (Published 24Apr2020)

View FDA News Release

 

Communication During a Pandemic (Published 24Apr2020)

View RAPS Article

 

Optimizing remote internal quality audits (Published 23Apr2020)

View RAPS Article

 

EMA details new drug supply monitoring system for COVID-19 (Published 21Apr2020)

View RAPS Article

 

Coronavirus (COVID-19) Update: FDA Authorizes First Test for Patient At-Home Sample Collection (Published 21Apr2020)

View FDA News Release

 

FDA expands COVID-19 drug compounding policy to smaller pharmacies (Published 21Apr2020)

View RAPS Article

 

FDA clarifies policies for reviewing ANDA amendments and supplements (Published 20Apr2020)

View RAPS Article

 

EMA updates on regulatory expectations amid COVID-19 (Published 20Apr2020)

View RAPS Article

 

COVID-19 IVD quality problems drive EC guidelines (Published 20Apr2020)

View RAPS Article

 

FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast Cancer (Published 17Apr2020)

View FDA News Release

 

NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options (Published 17Apr2020)

View NIH News Release

 

EU Regulatory Roundup: EMA shares advice on validated computer systems used in clinical trials (Published 16Apr2020)

View RAPS Article

 

Preparing for virtual regulatory meetings (Published 16Apr2020)

View RAPS Article

 

Coronavirus (COVID-19) Update: FDA Continues User-Fee Related Reviews Through COVID-19 (Published 16Apr2020)

View FDA News Release

 

Coronavirus (COVID-19) Update: FDA Encourages Recovered Patients to Donate Plasma for Development of Blood-Related Therapies (Published 16Apr2020)

View FDA News Release

 

Reagan-Udall Foundation launches COVID-19 treatment hub (Published 15Apr2020)

View RAPS Article

 

Harvard professors call on FDA to maintain review standards amid COVID-19 (Published 15Apr2020)

View RAPS Article

 

ICH adopts S11 guideline on nonclinical safety testing for pediatric drugs (Published 14Apr2020)

View RAPS Article

 

Asia Regulatory Roundup: Industry backs TGA plan to publish applications accepted for evaluation (Published 14Apr2020)

View RAPS Article

 

Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Decontaminate Millions of N95 Respirators (published 12Apr2020)

View FDA News Release

 

Coronavirus (COVID-19) Update: FDA Authorizes Blood Purification Device to Treat COVID-19 (Published 10Apr2020)

View FDA News Release

 

EMA stands up task force to oversee regulatory response to COVID-19 (Published 9Apr2020)

View RAPS Article

 

Regulators urge RCTs with control arms for COVID-19 drug trials (Published 09Apr2020)

View RAPS Article

 

New system to speed industry-EMA interactions on drug shortages (Published 06Apr2020)

View RAPS Article

 

FDA drug review times reflective of 4 key features, GAO finds (Published 06Apr2020)

View RAPS Article

 

Why FDA’s Issuance of EUAs are not ‘approvals’ and why that matters (Published 03Apr2020)

View RAPS Article

 

ICH: MedDRA updated with supplemental codes for coronavirus (Published 01Apr2020)

View RAPS Article

 


 

Explore-More-Image-1